SONN - Sonnet BioTherapeutics Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Princeton,
United States
Type: Equity
SONN price evolution
SONN
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.39 | $1.7 | $3.05 | $5.22 |
| Short term investments | ||||
| Net receivables | $0.45 | $1.34 | ||
| Inventory | ||||
| Total current assets | $13.05 | $4.6 | $5.41 | $7.17 |
| Long term investments | ||||
| Property, plant & equipment | $0.27 | $0.28 | $0.3 | $0.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.27 | $0.34 | $0.42 | $0.32 |
| Total investments | ||||
| Total assets | $13.31 | $4.94 | $5.83 | $7.49 |
| Current liabilities | ||||
| Accounts payable | $4.5 | $4.57 | $4.75 | $3.02 |
| Deferred revenue | $0.09 | $0.13 | $0.17 | $0.23 |
| Short long term debt | $0.07 | $0.05 | $0.05 | $0.05 |
| Total current liabilities | $7.77 | $8.29 | $8.16 | $6.5 |
| Long term debt | $0.17 | $0.19 | $0.2 | $0.22 |
| Total noncurrent liabilities | $0.17 | $0.19 | $0.2 | $0.22 |
| Total debt | $0.24 | $0.24 | $0.26 | $0.27 |
| Total liabilities | $7.94 | $8.48 | $8.37 | $6.73 |
| Shareholders' equity | ||||
| Retained earnings | -$102.62 | -$96.95 | -$91.41 | -$83.98 |
| Other shareholder equity | ||||
| Total shareholder equity | $5.37 | -$3.54 | -$2.54 | $0.76 |
| (in millions $) | 30 Oct 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.05 | $27.62 | $7.35 | $0.5 |
| Short term investments | ||||
| Net receivables | $0.13 | |||
| Inventory | $0.29 | |||
| Total current assets | $5.41 | $28.81 | $7.64 | $1.17 |
| Long term investments | $0.38 | |||
| Property, plant & equipment | $0.3 | $0.18 | $0.27 | $17.3 |
| Goodwill & intangible assets | $12.22 | |||
| Total noncurrent assets | $0.42 | $0.18 | $0.36 | $30.36 |
| Total investments | $0.38 | |||
| Total assets | $5.83 | $28.99 | $7.99 | $31.53 |
| Current liabilities | ||||
| Accounts payable | $4.75 | $3.78 | $2.06 | $8.17 |
| Deferred revenue | $0.17 | $0.52 | $0.5 | $0.96 |
| Short long term debt | $0.05 | $0.1 | $0.1 | $9.93 |
| Total current liabilities | $8.16 | $6.7 | $4.72 | $18.1 |
| Long term debt | $0.2 | $0.03 | $0.25 | $14.38 |
| Total noncurrent liabilities | $0.2 | $0.03 | $0.25 | $16.59 |
| Total debt | $0.26 | $0.13 | $0.35 | $24.31 |
| Total liabilities | $8.37 | $6.73 | $4.97 | $34.68 |
| Shareholders' equity | ||||
| Retained earnings | -$91.41 | -$61.69 | -$36.71 | -$75.07 |
| Other shareholder equity | -$0.05 | |||
| Total shareholder equity | -$2.54 | $22.26 | $3.02 | -$3.61 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.04 | $0.04 | $0.06 | $0.06 |
| Cost of revenue | ||||
| Gross Profit | $0.04 | $0.04 | $0.06 | $0.06 |
| Operating activities | ||||
| Research & development | $3.82 | $3.75 | $5.12 | $5.65 |
| Selling, general & administrative | $1.88 | $1.9 | $2.32 | $2.28 |
| Total operating expenses | $5.7 | $5.65 | $7.44 | $7.93 |
| Operating income | -$5.66 | -$5.61 | -$7.38 | -$7.87 |
| Income from continuing operations | ||||
| EBIT | -$5.67 | -$5.54 | -$7.44 | -$7.88 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$5.67 | -$5.54 | -$7.44 | -$7.88 |
| Income (for common shares) | -$5.67 | -$5.54 | -$7.44 | -$7.88 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.35 | $0.48 | $30.14 | |
| Cost of revenue | $28.9 | |||
| Gross Profit | $0.35 | $0.48 | $1.24 | |
| Operating activities | ||||
| Research & development | $21.44 | $16.63 | $9.88 | |
| Selling, general & administrative | $8.58 | $8.94 | $7.53 | $5.97 |
| Total operating expenses | $30.02 | $25.57 | $24.24 | $17.32 |
| Operating income | -$29.67 | -$25.09 | -$24.24 | -$16.08 |
| Income from continuing operations | ||||
| EBIT | -$29.72 | -$24.98 | -$24.29 | -$16.98 |
| Income tax expense | $0.07 | |||
| Interest expense | -$0.02 | $0.67 | ||
| Net income | ||||
| Net income | -$29.72 | -$24.98 | -$24.27 | -$17.73 |
| Income (for common shares) | -$29.72 | -$24.98 | -$65.6 | -$17.84 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$5.67 | -$5.54 | -$7.44 | -$7.88 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.02 | $0.02 | $0.02 |
| Business acquisitions & disposals | -$0.02 | -$0.87 | ||
| Stock-based compensation | $0.06 | $0.09 | $0.09 | $0.11 |
| Total cash flows from operations | -$4.7 | -$5.92 | -$6.16 | -$7.82 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.26 | -$0.02 | -$0.59 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $14.65 | $4.56 | $1.84 | |
| Net borrowings | ||||
| Total cash flows from financing | $14.65 | $4.56 | $4.01 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $9.69 | -$1.35 | -$2.17 | -$8.41 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$29.72 | -$24.98 | -$24.27 | -$17.73 |
| Operating activities | ||||
| Depreciation | $0.09 | $0.1 | $0.06 | $3.54 |
| Business acquisitions & disposals | -$0.9 | $0.53 | ||
| Stock-based compensation | $0.88 | $1.38 | $0.37 | $0.15 |
| Total cash flows from operations | -$27.69 | -$22.55 | -$15.61 | -$4.05 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.08 | -$0.47 | |
| Investments | ||||
| Total cash flows from investing | -$0.9 | -$0 | -$0.08 | $0.68 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.84 | $42.85 | $19.07 | $2.85 |
| Net borrowings | -$0.02 | $0.13 | ||
| Total cash flows from financing | $4.01 | $42.83 | $23.01 | $3.34 |
| Effect of exchange rate | $0 | |||
| Change in cash and equivalents | -$24.57 | $20.27 | $7.31 | -$0.02 |
News
Fundamentals
| Market cap | $10.25M |
|---|---|
| Enterprise value | -$903.38K |
| Shares outstanding | 20.50M |
| Revenue | $198.52K |
|---|---|
| EBITDA | -$26.44M |
| EBIT | -$26.52M |
| Net Income | -$26.52M |
| Revenue Q/Q | -61.77% |
| Revenue Y/Y | -71.99% |
| P/E ratio | -0.39 |
|---|---|
| EV/Sales | -4.55 |
| EV/EBITDA | 0.03 |
| EV/EBIT | 0.03 |
| P/S ratio | 51.63 |
| P/B ratio | 1.91 |
| Book/Share | 0.26 |
| Cash/Share | 0.56 |
| EPS | -$1.29 |
|---|---|
| ROA | -335.99% |
| ROE | -186.39K% |
| Debt/Equity | -3.30 |
|---|---|
| Net debt/EBITDA | 0.13 |
| Current ratio | 1.68 |
| Quick ratio | 1.68 |